

HLA G Antibody

Rabbit mAb Catalog # AP91116

Product Information

ApplicationWBPrimary AccessionP17693ReactivityHumanClonalityMonoclonal

Other Names HLA G antigen; MHC class I antigen G; HLA-G; HLA60; HLAG;

IsotypeRabbit IgGHostRabbitCalculated MW38224

Additional Information

Dilution WB 1:500~1:2000 **Purification** Affinity-chromatography

Immunogen A synthesized peptide derived from human HLA G

Description Involved in the presentation of foreign antigens to the immune system. Plays

a role in maternal tolerance of the fetus by mediating protection from the

deleterious effects of natural killer cells, cytotoxic T lymphocytes,

macrophages and mononuclear cells.

Storage Condition and Buffer Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium

azide and 50% glycerol. Store at +4°C short term. Store at -20°C long term.

Avoid freeze / thaw cycle.

Protein Information

Name HLA-G {ECO:0000303|PubMed:1570318, ECO:0000312|HGNC:HGNC:4964}

Function [Isoform 1]: Non-classical major histocompatibility class Ib molecule

involved in immune regulatory processes at the maternal-fetal interface (PubMed:19304799, PubMed:23184984, PubMed:29262349). In complex with B2M/beta-2 microglobulin binds a limited repertoire of nonamer self-peptides derived from intracellular proteins including histones and ribosomal proteins (PubMed:7584149, PubMed:8805247). Peptide-bound HLA-G-B2M complex acts as a ligand for inhibitory/activating KIR2DL4, LILRB1 and LILRB2 receptors on uterine immune cells to promote fetal development while maintaining maternal- fetal tolerance (PubMed:16366734, PubMed:19304799, PubMed:20448110, PubMed:23184984, PubMed:27859042,

PubMed:<u>29262349</u>). Upon interaction with KIR2DL4 and LILRB1 receptors on decidual NK cells, it triggers NK cell senescence-associated secretory phenotype as a molecular switch to promote vascular remodeling and fetal

growth in early pregnancy (PubMed: 16366734, PubMed: 19304799,

PubMed: 23184984, PubMed: 29262349). Through interaction with KIR2DL4

receptor on decidual macrophages induces pro-inflammatory cytokine production mainly associated with tissue remodeling (PubMed:19304799). Through interaction with LILRB2 receptor triggers differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:20448110, PubMed:27859042). May play a role in balancing tolerance and antiviral-immunity at maternal-fetal interface by keeping in check the effector functions of NK, CD8+ T cells and B cells (PubMed:10190900, PubMed:11290782, PubMed:24453251). Reprograms B cells toward an immune suppressive phenotype via LILRB1 (PubMed:24453251). May induce immune activation/suppression via intercellular membrane transfer (trogocytosis), likely enabling interaction with KIR2DL4, which resides mostly in endosomes (PubMed:20179272, PubMed:26460007). Through interaction with the inhibitory receptor CD160 on endothelial cells may control angiogenesis in immune privileged sites (PubMed:16809620).


Cellular Location

[Isoform 1]: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane. Early endosome membrane [Isoform 2]: Cell membrane; Single-pass type I membrane protein [Isoform 4]: Cell membrane; Single-pass type I membrane protein [Isoform 6]: Secreted Cell projection, filopodium membrane. Note=HLA-G trogocytosis from extravillous trophoblast's filopodia occurs in the majority of decidual NK cells.

Tissue Location

Expressed in adult eye (PubMed:1570318). Expressed in immune cell subsets including monocytes, myeloid and plasmacytoid dendritic cells and regulatory T cells (Tr1)(at protein level) (PubMed:20448110). Secreted by follicular dendritic cell and follicular helper T cells (PubMed:24453251) [Isoform 7]: Expressed in placenta, amniotic membrane, skin, cord blood and peripheral blood mononuclear cells

Images



Western blot analysis of HLA G expression in Jurkat cell lysate.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.